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Anti-cancer drugs generally have immunosuppressive  effects (1), which presents a 
serious clinical problem. Under selected conditions, cyclophosphamide  (CPM)  has an 
immunopotentiating effect on the delayed hypersensitivity reaction (DHR; 2-4). This 
effect has been attributable to the interruption of a feedback control to the effector T 
cells by B cells (2, 5) and/or by suppressor T cells (4, 5). Recently, similar phenomena 
have  been  reported  in  other  cell-mediated  (6,  7)  and  tumor  immunities  (8-10). 
Immunopotentiating  effects  of CPM  appear  to  take  place  preferentially  in  vivo, 
suggesting  that  such  effects may  be  due  to a  biological  consequence  of diffuse cell 
damage with CPM,  rather than to a unique biochemical action on selected popula- 
tions of lymphoid cells. 
The presence of naturally occurring suppressor T  cells (11)  and the effect of CPM 
on  them  have  been  reported  previously  (4,  12).  Here,  we  report  that  anti-cancer 
agents other than CPM also exhibit potentiating effects on the DHR when they are 
administered according to schedules of current clinical anti-cancer therapy. 
Materials and Methods 
Mice.  Inbred C57BL/6Cr mice were purchased from the Shizuoka Cooperative Association 
for Experimental Animals (Hamamatsu, Japan). 
Antigen.  Methylated human  serum  albumin  (MHSA)  prepared by the methanol-hydro- 
chloric acid method (13) was kindly donated by Dr. S. Morikawa, Shimanc Medical University. 
Anti-Cancer Drugs.  CPM  and  vincristine  (VCR)  were  purchased  from  Shionogi, Osaka, 
Japan; carbazylquinone (CQ) was obtained from Sankyo, Tokyo, Japan; nitrogen mustard-N- 
oxide (NM-N-O)  was purchased from Yoshitomi, Osaka; mitomycin c  (MMC),  adriamycin 
(ADM), and 5-fluorouracil (5-FU) were purchased from Kyowa Hakko, Tokyo; methotrexate 
(MTX) was obtained from Lederle Japan, Tokyo; cyclocytidine (Cyclo C) was purchased from 
Yamanouchi, Tokyo; and N,N',N"-triethylenethiophosphoramide (thio-TEPA) was obtained 
from Sumitomo Kagaku, Osaka. Drugs were given to mice intraperitoneally before sensitization. 
As described in the previous work with CPM (12), the dose of every anti-cancer drug was fixed 
to ~  of LD~0: CPM,  150 mg/kg; CO.)., 1.5 mg/kg; NM-N-O, 30 mg/kg; MMC, 2 mg/kg; thio- 
TEPA, 7.5 mg/kg; ADM, 5 mg/kg; 5-FU, 100 mg/kg; MTX, 40 mg/kg; Cyclo-C, 1,500 mg/ 
kg; and VCR,  1 mg/kg. In an experiment of intermittent treatments with CPM or 5-FU, each 
drug was administered once, twice, or three times at  1-wk intervals with each dose being % of 
LDs0. In an experiment of consecutive treatments with the drugs, CPM  (I0 mg/kg) or 5-FU 
(7 mg/kg) was given every evening for 14 consecutive days to make doses equivalent to % of 
LDs0. 
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TABLE  I 
Effect of Various Alkylating Drugs on the DHR 
Drug  DHR on day 13 (0.1 mm)  Body weight 
g 
--  5.3±  1.6  25.1  ±0.7 
CPM  9.7 ±  1.3  24.1 ±  0.5 
CQ  15.6 ±  1.8"  26.3 ±  0.3 
Thio-TEPA  15.2 ±  1.8"  25.7 ±  0.5 
NM-N-O  13.5 ±  2.1~  25.5 ±  0.4 
Male C57BL/6Cr mice were given alkylating drugs by % of LD60, intraperitoneally, 4 
d before sensitization.  Mice were 3 mn old at sensitization.  Each group consisted  of six 
animals. The data are shown as mean ±  SE. 
* P<  0.01 compared with drug (--). 
P <  0.02 compared with drug (--). 
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TABLE II 
Effect of Various Anti-cancer Drugs on the DHR 
Classification  DHR on day 13 
of drug  Drug  (0.1 mm)  Body weight 
g 
--  3.8  ±  1.6  19.0 ±  0.4 
CCNS drug  MMC  13.8 ±  2.4*  19.1 ±  0.7 
ADM  13.0 ±  2.3~:  19.8 ±  0.8 
CCS drug  5-FU  14.2 ±  1.3"  19.7 ±  0.4 
VCR  11.8 ±  1.8~  19.4 ±  0.7 
Cyclo-C  11.2 ±  0.7*  20.6 ±  0.2 
MTX  10.4 ±  1.6§  19.6 ±  0.4 
Female C57BL/6Cr mice were given various anti-cancer drugs by % of LDs0, intraper- 
itoneally, 4  d  before sensitization.  Mice were 3  mo old at  sensitization.  Each  group 
consisted  of five animals. 
* P <  0.01 compared with drug (--). 
:[: P <  0.02 compared with drug (--). 
§ P <  0.05 compared with drug (--). 
Sensitization.  Sensitization for DHR was carried out by subcutaneous  injection into the hind 
footpad with 0.05 ml of emulsion  (5 mg/ml MHSA solution in phosphate-buffered  saline, pH 
7.1, and complete Freund's adjuvant, including  3 mg of dead H37RV tubercle bacilli/ml;  14). 
The sensitization was performed  4 d after the last drug treatment. 
DHR Assay.  The difference in footpad thickness before challenge and at 24 h after challenge 
was measured  and expressed as DHR in 0.1-mm units.  Challenge  with 0.02 ml of 0.1 mg/ml 
MHSA  solution  in  phosphate-buffered  saline  was  performed  around  the  l lth-13th  d  of 
sensitization  (14). 
Statistical Analysis.  All data are presented as means ± standard errors. Statistical comparisons 
were performed using the Student's t test. 
Results 
When the effects on the  DHR of several  alkylating agents including CPM were 
examined, there was a  significant enhancement of DHR (Table I). CQ~ thio-TEPA, 
and NM-N-O were greater in their potency in DHR enhancement than CPM. These 
alkylating drugs are now categorized as cell cycle nonspecific (CCNS) drugs (15). To 
examine whether the observed effects are specific for CCNS, we employed both CCNS 
and cell cycle specific (CCS) drugs (Table II). Essentially similar results were obtained 
with  CCS  drugs, suggesting that  potentiation  of DHR with  anti-cancer drugs  is  a 
common  phenomenon.  A  transfer  of 2  ×  107  thymus  cells  from  untreated  mice 
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TABL~ III 
Effect of Intermittent  High Dose Treatments with CPM or 5-FU on the DHR 
Number of  DHR on day  11  Body weight 
Drug  injections  (0.1  mm) 
g 
--  0  9.0 ±  1.1  25.7 ±  0.7 
CPM  1  14.8 ±  1.3"  21.2 ±  0.7 
CPM  2  14.5  ±  1.6~  26.2 ±  0.9 
CPM  3  20.3 ±  0.6§  25.3 ±  0.9 
5-FU  1  13.0 ±  1.311  22.7 ±  0.6 
5-FU  2  14.5  ±  1.811  24.7 ±  1.0 
5-FU  3  13.5 ±  3.8  24.3 ±  0.8 
Male C57BL/6Cr mice were given CPM or 5-FU by % of LDso, intraperitoneally once, 
twice, or three times  at  t-wk intervals.  Sensitization  was on  4  d  after the  last  drug 
treatment, Mice were 3.5-mo-old at sensitization. Each group consisted of six animals. 
* P  <  0.01 compared with drug (--). 
:~ P  <  0.02 compared with drug (--). 
§ P <  0.001  compared with drug (--). 
[I P  <  0.05 compared with drug (--). 
TABLE  IV 
Effect of Consecutive Smaller Dose  Treatments  with CPM or 5-FU on the 
DHR 
Interval be- 
tween the last  DHR on day  12  Body weight 
Drug  treatment and  (0.1  ram) 
sensitization 
d  g 
--  --  5.3 ±  0.7  20.9 +  0.5 
CPM  1  4.5 +  0.8  20.4 -4- 0.4 
CPM  4  7.3 ±  0.9  20.1  ±  0.2 
CPM  7  5.0 +  0.9  22.1  ±  0.6 
5-FU  1  6.0 ±  1.4  20.8 ±  0.3 
5-FU  4  5.3 ±  0.6  21.6 ±  0.3 
5-FU  7  4.6 ±  0.8  21.6 ±  0.3 
Female C57BL/6Cr mice were given CPM or 5-FU intraperitoneally for  14 consecutive 
days. The total dose was equivalent to % of LDs0 for each drug. Mice were 3.5-mo-old at 
sensitization. Each group consisted of 10 animals. 
primary  target  of these  drugs  might  therefore be  naturally  occurring suppressor T 
cells, in keeping with our previous results, which showed that CPM  (a CCNS  drug) 
eliminated suppressor T  cell activity involved in DHR  (4,  12). 
To examine whether the immunopotentiating effects of these drugs depend on the 
protocols  of  the  treatments,  we  compared  the  effects  of  intermittent  high  dose 
treatments and those of consecutive smaller dose treatments with drugs on the DHR 
(Tables  III and IV).  The data clearly demonstrated that  the intermittent  high dose 
treatments are effective in enhancement of DHR  (Table III), whereas the consecutive 
smaller dose treatments have no effects on the DHR, although the total dose given to 
each animal was % of LDs0 (Table IV). 
Discussion 
Anti-cancer drugs are generally classified  as either CCS or CCNS  on the basis of 
their effects on cells (15,  16). CCS drugs are usually schedule dependent  and require 
maintenance  of drug  concentration  for  a  period  of time  sufficient  to  affect  tumor 
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doses because of the greater sensitivity of tumor cells  compared with that of normal 
cells.  CPM was once classified as a  CCS drug (16),  but was later considered to be a 
CCNS drug (15). In any case, superiority of treatment with intermittent high doses is 
accepted in CPM anti-cancer therapy (17,  18). The intermittent  high dose therapy 
was also reported to be valid for some CCS drugs such as 5-Fu  (19)  and MTX  (20, 
21).  Our present study clearly demonst,'ated that the intermittent high dose therapy 
with anti-cancer drugs is effective in immunopotentiation. 
We  previously  proposed  that  the  principal  reason  the  suppressor  activity  was 
eliminated after CPM treatment in vivo is that suppressor T  cells are recovered more 
slowly or more insufficiently from damage than the other cells,  effector T  cells,  and 
macrophages (4, 12). This would suggest that a clue for the differential elimination is 
based on the biological properties of the host rather than on a  biochemical property 
of CPM. The present work, together with others  (22-25), supports this idea because 
many other cytotoxic agents besides CPM exhibited similar effects on the DHR. It is 
quite likely that some, if not all, suppressor cells or their precursors might be more or 
less sensitive to cytotoxic agents such as CPM (26). 
CPM is often used as an immunopotentiator in the studies on cellular immunology 
(2-7) and tumor immunology (8-10). The activation of CPM by microsomal enzymes 
in the liver is necessary for the action as a cytotoxic agent (27).  The enzyme activity 
for the activation depends on the strain and age of the mouse (M. Goto, A. Mitsuoka, 
M. Sugiyama, and M. Kitano, unpublished data). In addition, these enzymes can be 
induced  by various  pretreatments  (28).  The  relative  level  of the  active  form(s)  in 
CPM-treated animals is undetermined. Other anti-metabolic agents reported in this 
paper have similar effects on the DHR. These drugs do not require  the conversion 
into  the  active  form  as  does  CPM,  and  thus  may be  readily  assessed  as  cytotoxic 
agents for immunoregulation. 
Summary 
Delayed hypersensitivity reaction in  mice was commonly enhanced with  various 
anti-cancer agents administered as single or intermittent high doses but not consecu- 
tive divided doses. The effect of anti-cancer agents on the delayed hypersensitivity 
reaction was thought to be due to elimination of suppressor T  cell activity. 
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